Pharmaceuticals company Windlas Biotech announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from operations stood at Rs 187.0 crore as against Rs 152.7 crore, a growth of 22.5% YoY. EBITDA stood at Rs 23.0 crore as against Rs 18.7 crore YoY, a growth of 23.3% YoY. EBITDA Margin (%) came in at 12.3%. PAT stood at Rs 15.6 crore as against Rs 14.0 crore YoY, a growth of 11.5% YoY. PAT Margin (%) came in at 8.4%. H1FY25 Financial Highlights: Revenue from operations stood at Rs 362.2 crore as against Rs 297.5 crore, a growth of 21.7% YoY. EBITDA stood at Rs 43.9 crore as against Rs 35.8 crore YoY, a growth of 22.6% YoY. EBITDA Margin (%) came in at 12.1%. PAT stood at Rs 29.1 crore as against Rs 26.1 crore YoY, a growth of 11.7% YoY. PAT Margin (%) came in at 8.0%. Hitesh Windlass, Managing Director, Windlas Biotech said: "The Indian Pharmaceutical Market (IPM) reported a YoY growth of 8% in Q2FY25, with only a modest volume increase of 0.4%. Despite low volume industry growth, we are pleased to reveal another strong quarter of financial performance, achieving a revenue growth of 22% in Q2FY25 as well as in H1FY25. This outperformance was fueled by strong momentum in our Trade Generics and institutional vertical alongside a steady contribution from our CDMO vertical. We remain optimistic about the growth prospects in our Generic Formulations CDMO vertical as pharmaceutical companies continue to shift business to reliable, high-quality manufacturing partners. Providing Accessible, Affordable, and Authentic medication to the semi-urban and rural markets in India continues to be our focus in Trade Generics and Institutional vertical. Schemes like Ayushman Bharat and Jan Aushadhi continue to strengthen acceleration of institutional sales. For Export vertical, we continue to explore more new markets to meet the growing global demand for affordable generics. We are on track for capacity expansion of Plant 2. As updated earlier, the shortlisted brownfield facility in Selaqui, Dehradun has been acquired to meet our capacity expansion needs. The revenue generation from the injectables facility is expected to commence from Q3 FY25, as production batches complete their required stability testing. The Company paid a dividend of Rs 5.5 per share amounting to Rs 11.5 crore for FY24 in October 2024. The EPS rose to Rs 13.97 in H1FY25 and Rs 7.49 in Q2FY25, registering a YoY growth of 11%.” Komal Gupta, CEO & CFO - Windlas Biotech, said: “Our Highest ever quarterly revenue streak holds steady for 7th quarter. Windlas Biotech remains focused on expanding our outreach, driving efficiencies and delivering high-quality pharmaceutical products to meet the evolving needs of our customers and patients. In Generic Formulation CDMO vertical we have improved our customer engagement and service levels. In H1FY25, this vertical generated revenue of Rs 272.2 crore, showing a 19% YoY growth and for Q2FY25, revenue in this vertical reached Rs 136.3 crore, reflecting a 16% increase compared to last year. Trade Generics and Institutional vertical continues to be propelled by widening of product portfolio as well as expansion of distribution network. By adding more institutions and launching new products, we’ve extended our reach significantly - positioning us well for continued growth. In H1FY25, this vertical achieved revenue of Rs 77 crore, an increase of 30% YoY. For Q2FY25, we clocked revenue of Rs 41.9 crore, reflecting a 48% growth YoY. Our exports vertical reported revenue of Rs 12.9 crore in H1FY25, a 26% increase YoY, with Q2FY25 showing a revenue of Rs 8.8 crore reflecting 35% growth YoY. Our Injectables facility is yet to contribute revenue even though its OPEX and depreciation are included in H1 financials. In H1FY25, WBL revenue stood at Rs 362 crore, reflecting a 22% YoY growth. EBITDA saw a rise of 23% YoY, reaching Rs 44 crore. PAT came in at Rs 29 crore, reflecting a 12% YoY rise. For Q2FY25, the company’s revenue reached Rs 187 crore, reflecting a 22% YoY growth. EBITDA stood at Rs 23 crore, up by 23%, YoY and PAT was Rs 16 crore, registering a 12% YoY increase. As on 30th September, the company’s liquidity position is at Rs 200 crore (despite capex of Rs 48 crore in H1FY25). We are excited about the substantial growth opportunities in our space and are dedicated to maintaining growth momentum across all our business verticals.” Result PDF